E Bernasconi

Summary

Country: Switzerland

Publications

  1. ncbi request reprint [Endemic and imported severe leptospirosis (Weil's disease) in southern Switzerland]
    E Bernasconi
    Dipartimento di Medicina, Ospedale Regionale, Lugano
    Schweiz Med Wochenschr 130:1487-92. 2000
  2. ncbi request reprint Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000
    E Bernasconi
    Infectious Diseases Unit, Department of Medicine, Regional Hospital, Lugano, Switzerland
    Swiss Med Wkly 131:433-7. 2001
  3. ncbi request reprint Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
    Enos Bernasconi
    Hospital of Lugano, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 31:50-5. 2002
  4. pmc Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study
    Regina B Osih
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    AIDS Res Hum Retroviruses 26:1239-46. 2010
  5. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010
  6. ncbi request reprint Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
    J Fellay
    University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 358:1322-7. 2001
  7. doi request reprint Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 51:1090-8. 2010
  8. pmc Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance
    Julia Di Iulio
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Hepatology 53:1446-54. 2011
  9. doi request reprint Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy
    L Magenta
    Division of Infectious Diseases, Hospital of Lugano, Switzerland
    AIDS Res Hum Retroviruses 27:525-33. 2011
  10. doi request reprint A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort
    Patrick Taffe
    Data Center, Swiss HIV Cohort Study, CHUV, Lausanne, Switzerland
    Stat Med 27:4835-53. 2008

Detail Information

Publications70

  1. ncbi request reprint [Endemic and imported severe leptospirosis (Weil's disease) in southern Switzerland]
    E Bernasconi
    Dipartimento di Medicina, Ospedale Regionale, Lugano
    Schweiz Med Wochenschr 130:1487-92. 2000
    ..Patients presenting with acute renal failure and jaundice, but only mild-to-moderate elevation of transaminases, are suspect for leptospirosis regardless of travel to a tropical or subtropical country...
  2. ncbi request reprint Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000
    E Bernasconi
    Infectious Diseases Unit, Department of Medicine, Regional Hospital, Lugano, Switzerland
    Swiss Med Wkly 131:433-7. 2001
    ..To analyse the data from Swiss nationwide voluntary reporting on non-occupational HIV-postexposure prophylaxis (HIV-PEP) by prescribing physicians...
  3. ncbi request reprint Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
    Enos Bernasconi
    Hospital of Lugano, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 31:50-5. 2002
    ..1 [95% CI, 0.6-1.8]; 6-24 months, OR = 2.4 [95% CI, 1.7-3.5]; and >24 months, OR = 3.2 [95% CI, 2.4-4.3]). This study confirms the association between the use of stavudine and lipodystrophy...
  4. pmc Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study
    Regina B Osih
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    AIDS Res Hum Retroviruses 26:1239-46. 2010
    ..Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more expensive alternates are not available...
  5. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010
    ....
  6. ncbi request reprint Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
    J Fellay
    University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 358:1322-7. 2001
    ..Such data provides a reference for regimen-specific and compound-specific adverse events and could be useful in postmarketing analyses of toxic effects...
  7. doi request reprint Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 51:1090-8. 2010
    ..Recent genome-wide association studies have reliably associated multiple single nucleotide polymorphisms (SNPs) to DM in the general population...
  8. pmc Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance
    Julia Di Iulio
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Hepatology 53:1446-54. 2011
    ....
  9. doi request reprint Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy
    L Magenta
    Division of Infectious Diseases, Hospital of Lugano, Switzerland
    AIDS Res Hum Retroviruses 27:525-33. 2011
    ..Despite an increase in the majority of measured lipids and lipoproteins particularly in the first year after initiation, we could not detect an obvious increase of cardiovascular risk resulting from the observed lipid changes...
  10. doi request reprint A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort
    Patrick Taffe
    Data Center, Swiss HIV Cohort Study, CHUV, Lausanne, Switzerland
    Stat Med 27:4835-53. 2008
    ..Results of simulation studies indicated that the imputation procedure worked well, despite the intrinsic high volatility of the CD4 marker...
  11. pmc Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    PLoS Pathog 6:e1000781. 2010
    ..Overall, changes in global RNA expression reflect responses to viral replication rather than a mechanism that might explain viral control...
  12. pmc HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy...
  13. doi request reprint High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients
    Nicolas J Mueller
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital of Zurich, Zurich, Switzerland
    AIDS 24:1127-34. 2010
    ..To evaluate the prevalence of 25-hydroxyvitamin D [25(OH)D] deficiency in HIV-positive patients, a population at risk for osteoporosis...
  14. doi request reprint Assessment of potential drug-drug interactions at hospital discharge
    Raffaela Bertoli
    Servizio di consulenza sui farmaci e Centro Regionale di Farmacovigilanza, Ospedale Regionale di Lugano, Lugano, Lugano, Switzerland
    Swiss Med Wkly 140:w13043. 2010
    ..The relevant clinical information was reported to the treating physicians...
  15. ncbi request reprint Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
    Gilbert Greub
    University Hospital, Lausanne, Switzerland
    AIDS 16:1967-9. 2002
  16. ncbi request reprint Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
    Philip E Tarr
    Infectious Diseases Service, University Hospital, Lausanne, Switzerland
    J Infect Dis 191:1419-26. 2005
    ..Single-nucleotide polymorphisms in genes involved in lipoprotein and adipocyte metabolism may explain why dyslipidemia and lipoatrophy occur in some but not all antiretroviral therapy (ART)-treated individuals...
  17. doi request reprint Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    Circ Cardiovasc Genet 2:621-8. 2009
    ..Recent genome-wide association studies have reliably associated common SNPs to dyslipidemia in the general population...
  18. doi request reprint In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
    Julia Di Iulio
    Institute of Microbiology Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 19:300-9. 2009
    ..We hypothesize that genetic variability in this gene may contribute to the particularly high, unexplained variability in EFV exposure in individuals with limited CYP2B6 function...
  19. doi request reprint The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir
    Sara Colombo
    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    J Infect Dis 198:864-7. 2008
    ..2%, respectively; P < .0001). Therefore, HCP5 genotyping could serve as a simple screening tool for ABC-HSR, particularly in settings where sequence-based HLA typing is not available...
  20. ncbi request reprint The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study
    Christian Felley
    Division of Gastroenterology, and Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    AIDS 18:1521-7. 2004
    ..This study will evaluate the frequency of CFTR mutations and SPINK-1 polymorphisms in HIV-positive patients with clinical pancreatitis or asymptomatic elevation of serum pancreatic enzymes...
  21. doi request reprint Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study
    Jean Jacques Gonvers
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Swiss Med Wkly 140:w13055. 2010
    ..Secondary endpoints were to evaluate predictors of sustained virological response (SVR) and frequency of side-effects...
  22. doi request reprint Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication
    Donatella Ciuffreda
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, CHUV, Lausanne, Switzerland
    Eur J Immunol 38:2665-77. 2008
    ..Therefore, the present results suggest that immune-based mechanisms may contribute to explain the accelerated course of HCV infection in conditions of HIV-1 co-infection and liver transplantation...
  23. ncbi request reprint Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study
    Olivia Keiser
    Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 43:550-5. 2006
    ..According to current recommendations, HIV-infected women should have at least 1 gynecologic examination per year...
  24. ncbi request reprint All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population
    Olivia Keiser
    Data Centre of the Swiss HIV Cohort Study, Lausanne, Switzerland
    AIDS 18:1835-43. 2004
    ..Mortality within the Swiss HIV Cohort Study for the years 1990-2001 was compared with the mortality of the general Swiss population...
  25. doi request reprint Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Clin Infect Dis 46:1299-309. 2008
    ..We aimed to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss HIV Cohort Study...
  26. ncbi request reprint Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Clin Infect Dis 41:361-72. 2005
    ..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
  27. doi request reprint CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
    ....
  28. ncbi request reprint Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistr 100, CH 8091 Zurich, Switzerland
    Arch Intern Med 167:1782-90. 2007
    ..Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed...
  29. ncbi request reprint CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
    Marcel Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    Antivir Ther 12:889-97. 2007
    ..This study aimed to identify predictive factors for long-term CD4+ T-cell increase in treatment-naive patients starting combination antiretroviral therapy (cART)...
  30. ncbi request reprint Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis
    Christina Eigenmann
    Division of Infectious Diseases, University Hospital Berne, Switzerland
    Clin Infect Dis 36:917-21. 2003
    ..Discontinuation of TMP-SMX prophylaxis against PCP is not associated with a significant increase in the incidence of bacterial pneumonia among patients with a sustained CD4 cell count increase to >200 cells/microL...
  31. ncbi request reprint Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
    Mathew Simcock
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
    Antivir Ther 12:931-9. 2007
    ..To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma...
  32. ncbi request reprint Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
    Marcel Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    AIDS 21:2201-7. 2007
    ....
  33. ncbi request reprint Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Switzerland
    Antivir Ther 12:1157-64. 2007
    ..Antiretroviral therapy (ART) decreases morbidity and mortality in HIV-infected patients but is associated with considerable adverse events (AEs)...
  34. ncbi request reprint Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
    Christoph A Fux
    Division of Infectious Diseases, University Hospital Berne, Berne, Switzerland
    Antivir Ther 12:1165-73. 2007
    ..A growing number of case reports have described tenofovir (TDF)-related proximal renal tubulopathy and impaired calculated glomerular filtration rates (cGFR). We assessed TDF-associated changes in cGFR in a large observational HIV cohort...
  35. ncbi request reprint Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 13:77-85. 2008
    ..The aim of this study was to explore the predictive value of longitudinal self-reported adherence data on viral rebound...
  36. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  37. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  38. doi request reprint Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study
    Thi Tuyet Nhung Vo
    VCHAP Project, Tropical Disease Hospital, Ho Chi Minh City, Vietnam
    J Infect Dis 197:1685-94. 2008
    ..Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment...
  39. doi request reprint Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era
    Emmanuelle Boffi El Amari
    Geneva University Hospital, Geneva, Switzerland
    AIDS 22:1019-28. 2008
    ..While many patients do well on highly active antiretroviral therapy, others have progressive disease and need chemotherapy. In order to predict which patients are at risk of unfavorable evolution, we established a prognostic score...
  40. ncbi request reprint Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy
    Mireia Arnedo
    Institute of Microbiology, University of Lausanne, Switzerland
    Pharmacogenet Genomics 17:755-64. 2007
    ..Single nucleotide polymorphisms in multiple genes involved in lipid transport and metabolism are presumed to modulate the risk of dyslipidemia in response to antiretroviral therapy...
  41. ncbi request reprint Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 45:111-9. 2007
    ..Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment...
  42. ncbi request reprint Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    HIV Clin Trials 8:77-85. 2007
    ..Based on a health care system approach, we investigated predictors for normalization of dyslipidemia in HIV-infected individuals receiving ART...
  43. ncbi request reprint Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting
    Vincenzo Puro
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Rome, Italy
    Eur J Epidemiol 19:577-84. 2004
    ..HIV resistance tests in the source and direct virus assays in the exposed HCW are not recommended routinely. These easy-to-use recommendations seek to maximise PEP effect while minimising its toxicity and inappropriate use...
  44. ncbi request reprint Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Blood 104:1784-92. 2004
    ..In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points...
  45. ncbi request reprint Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
    Gilbert R Kaufmann
    Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Antivir Ther 9:263-74. 2004
    ..Information about the virological response to sequential highly active antiretroviral therapy (HAART) for HIV infection is limited. The virological response to four consecutive therapies was evaluated in the Swiss HIV Cohort...
  46. pmc Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study
    Jim Young
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, Basle, CH 4031, Switzerland
    BMJ 328:15. 2004
    ..To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART)...
  47. ncbi request reprint CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
    Gilbert R Kaufmann
    Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Arch Intern Med 163:2187-95. 2003
    ..Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART...
  48. ncbi request reprint Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival
    Cornelia Staehelin
    Division of Infectious Diseases, University Hospital Berne, Berne, Switzerland
    AIDS 17:2237-44. 2003
    ....
  49. ncbi request reprint Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
    Christian Jaggy
    Swiss Re, Zurich, Switzerland
    Lancet 362:877-8. 2003
    ..Patients with successfully treated cancer have much the same excess death rates but are not excluded from life insurance policies...
  50. ncbi request reprint Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study
    Katja Wolf
    Basel Institute for Clinical Epidemiology and dagger Division of Infectious Diseases, University Hospital Basel, Switzerland
    J Acquir Immune Defic Syndr 33:494-9. 2003
    ..There is no evidence that self-reported unsafe sexual behavior is more prevalent among HIV-infected individuals with optimal viral suppression. However, unsafe sex is associated with other factors...
  51. ncbi request reprint A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
    Catherine Fagard
    Divisions of Infectious Diseases, University Hospital, Geneva, Geneva, Switzerland
    AIDS 17:1487-92. 2003
    ..To explore the effect of granulocyte macrophage colony stimulating factor (GM-CSF) on viral load and CD4 cell count during interruption of highly active antiretroviral therapy (HAART)...
  52. ncbi request reprint A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
    Catherine Fagard
    Division of Infectious Diseases, Geneva Unmiversity Hospital, 1211 Geneva 14, Switzerland
    Arch Intern Med 163:1220-6. 2003
    ..Many patients who started HAART earlier in their disease course than is currently recommended would like to discontinue, but it is unknown whether it is safe to do so...
  53. ncbi request reprint Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l
    Milos Opravil
    Division of Infectious Diseases, University Hospitals of Zurich, Switzerland
    AIDS 16:1371-81. 2002
    ..To evaluate the efficacy of early initiation of highly active antiretroviral therapy (HAART), we compared the clinical course of two nested, matched cohorts within the Swiss HIV Cohort Study...
  54. ncbi request reprint A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
    J Infect Dis 185:1251-60. 2002
    ....
  55. ncbi request reprint Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study
    Claudine Zellweger
    Division of Infectious Diseases, University Hospital of Berne, Berne, Switzerland
    AIDS 18:2047-53. 2004
    ..To assess the long-term safety of discontinuation of secondary anti-Pneumocystis prophylaxis in HIV-infected adults treated with antiretroviral combination therapy and who have a sustained increase in CD4 cell counts...
  56. ncbi request reprint Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
    Milos Opravil
    AIDS 18:2213-5. 2004
  57. ncbi request reprint Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study
    Barbara Hasse
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    AIDS Res Hum Retroviruses 20:909-15. 2004
    ..92 versus 2.17 years, p = 0.30). In conclusion, AVN could not be attributed to time on antiretroviral treatment, but patients with AVN had histories of more severe immunosuppression and a higher body mass index than controls...
  58. ncbi request reprint Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy
    Dorothea M Wunder
    Department of Obstetrics and Gynaecology, University Hospital of Berne, Berne, Switzerland
    Antivir Ther 12:261-5. 2007
    ..To assess the prevalence of abnormal testosterone and gonadotropin values in HIV-infected men before and after 2 years of combination antiretroviral therapy (cART)...
  59. ncbi request reprint Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission
    Luigia Elzi
    University Hospital Basel, Switzerland
    Clin Infect Dis 44:94-102. 2007
    ..We aimed to assess the effect of TST and preventive treatment of TB on the incidence of TB in the era of combination antiretroviral therapy in an area with low rates of TB transmission...
  60. ncbi request reprint CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet 368:459-65. 2006
    ..Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance...
  61. ncbi request reprint Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
    Annelies S Zinkernagel
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Antivir Ther 11:131-42. 2006
    ....
  62. ncbi request reprint Stable virulence levels in the HIV epidemic of Switzerland over two decades
    Viktor Müller
    Bioinformatics Group, Department of Plant Taxonomy and Ecology, Eotvos Lorand University, Budapest, Hungary
    AIDS 20:889-94. 2006
    ..To determine whether the virulence of HIV-1 has been changing since its introduction into Switzerland...
  63. ncbi request reprint Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, CH 4056 Basel, Switzerland
    J Acquir Immune Defic Syndr 41:385-92. 2006
    ..Adherence is one of the most crucial issues in the clinical management of HIV-infected patients receiving antiretroviral therapy (ART)...
  64. ncbi request reprint Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America
    Enrico Girardi
    Dipartimento di Epidemiologia, Istituto Nazionale per le Malattie Infettive L Spallanzani IRCCS, Via Portuense 292, 00149 Rome, Italy
    Clin Infect Dis 41:1772-82. 2005
    ..We obtained estimates of the incidence of tuberculosis (TB) among patients receiving HAART and identified determinants of the incidence...
  65. ncbi request reprint HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  66. ncbi request reprint Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy
    Dorothea Wunder
    Department of Obstetrics and Gynaecology, University Hospital of Berne, Switzerland
    AIDS 19:1837-42. 2005
    ..To assess the correlations between the hormone leptin and lipoatrophy in HIV-positive, treatment-naive patients on combination antiretroviral therapy (cART)...
  67. ncbi request reprint Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
    Jim Young
    Institut für klinisehe Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:585-91. 2005
    ..We report on medium-term lipid profiles (up to 5 years) for antiretroviral-naive patients starting NNRTI- and PI-based HAART in the Swiss HIV Cohort Study...
  68. ncbi request reprint Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
    Andri Rauch
    Division of Infectious Diseases, University Hospital Berne, Switzerland
    Clin Infect Dis 41:395-402. 2005
    ..Data on the incidence of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)-infected persons are sparse. It is controversial whether and how frequently HCV is transmitted by unprotected sexual intercourse...
  69. ncbi request reprint Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
    Jim Young
    Institut für Klinische Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:73-81. 2005
    ..Our objective is to show whether such associations are more or less likely for patients on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART...
  70. ncbi request reprint Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort
    Bernard Hirschel
    Division of Infectious Diseases, Geneva University Hospital, CH 1211 Geneva 14, Switzerland
    AIDS 16:381-5. 2002
    ..Switchers were matched to non-switchers on the basis of calendar time, CD4 cell count, and viral load...